Conditions: Metastatic Prostate Cancer
Keywords: Metastatic hormone refractory prostate cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 49
Healthy volunteers: no

Brief summary:
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

Detailed description:

Arms:
arm 1: Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m\^2. arm 2: Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2. arm 3: Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2. arm 4: Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2. arm 5: Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.

Interventions: intervention 1: Dasatinib intervention 2: Docetaxel
Intervention descriptions: intervention 1: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression intervention 2: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.

Protocol document: